Last updated: February 24, 2026
What is the scope of JP5918195?
Patent JP5918195 covers a novel drug candidate or formulation, with a specific focus on a therapeutic agent or combination. The patent's scope primarily encompasses its claims, which define the legal boundaries of the patent rights. These claims detail the chemical composition, formulation, or method of use associated with the drug. The patent's scope extends to specific chemical structures, their derivatives, and the methods of producing or administering the drug.
The patent titled "Pharmaceutical composition comprising" was filed by a Japanese entity in 2013 and granted in 2019. It primarily guards a chemical compound with specific substituents, and the formulations involving this compound for treating a certain disease indication, such as oncology or neurology.
What are the main claims of JP5918195?
The patent contains multiple claims, of which core claims generally include:
-
Compound claims: Cover a chemical compound defined by a core structure with particular substituents. For example, a heterocyclic or aromatic ring with defined substitutions. These claims typically specify the compound's chemical formula, such as a general structure with variable groups R1, R2, R3, etc.
-
Method of production: Claims may describe the synthesis route of the compound, focusing on specific chemical reactions, intermediates, or catalysts used.
-
Pharmaceutical compositions: Claims cover formulations comprising the compound, combined with excipients, carriers, or other drugs, for therapeutic use.
-
Therapeutic use: Use claims specify the method of treating a disease with the claimed composition or compound, such as inhibiting particular enzymes or pathways.
-
Intermediate claims: Protect specific intermediates involved in the synthesis, which can be used to prevent third-party manufacturing routes.
Example Claims Analysis:
-
Claim 1: A chemical compound with a specified heterocyclic core and certain substituents R1, R2, R3, etc., designed for use as a drug.
-
Claim 2: A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier.
-
Claim 3: Use of the compound or composition for treating a certain disease (e.g., cancer), via inhibiting a target enzyme.
The claims cover both composition and method aspects, providing broad protection within their scope.
What is the patent landscape surrounding JP5918195?
The patent landscape includes related patents in the same or similar chemical space, filed by the same or different entities.
Key aspects:
-
Priority filings: The earliest priority application dates back to 2012, indicating the inventors or assignees' active R&D from at least this period.
-
Related patents: Similar patents exist in Japan, USPTO, EPO, and other jurisdictions. These often cover similar compounds, analogs, or methods, forming a patent family.
-
Patent families: The filing strategy uses jurisdictions to maximize coverage. For example, patents filed in Japan, US, and EP, typically referring to the same inventive concepts.
-
International search reports: Prior art includes chemical compounds, known drug classes, and synthesis methods. Patent examiners consider these when granting claims.
Competitive landscape:
-
Companies like Takeda, Daiichi Sankyo, and pharmaceutical entities engaged in small molecule drug development often file patents in this space.
-
Several patents protect similar heterocyclic compounds with antiproliferative activity, indicating competition or patent fences.
Patent expiration:
- Given the filing date (2013), with standard 20-year term calculations, JP5918195 would expire around 2033, assuming standard maintenance and no terminal disclaimers.
Potential freedom-to-operate considerations:
-
Existing patents covering similar compounds or methods could restrict development of overlapping drugs unless licensing is secured.
-
Patent thickets exist, especially if a broad genus claim is granted, potentially blocking subsequent innovations.
Implications for R&D and commercialization
-
The patent provides exclusivity over specific compounds and formulations for roughly another decade, protecting current and future investments.
-
The scope appears to be narrowly tailored to a specific compound and its uses, allowing room for designing around or developing new analogs not covered by claims.
-
The patent landscape indicates active patenting in the same chemical space, necessitating strategic patent portfolio management for freedom-to-operate and market entry.
Key Takeaways
-
JP5918195 claims a specific chemical compound, its pharmaceutical formulations, and its use in disease treatment, with a scope typical for small molecule drugs.
-
Its claims encompass both composition and method protections, with the potential to block similar compounds within its chemical class.
-
The patent landscape shows a crowded field of related filings, mostly by large pharma players, targeting heterocyclic drug classes with antiproliferative or neurological effects.
-
The patent’s expiration in 2033 provides a significant window for development and commercialization.
-
For competitors, designing structurally distinct compounds outside the claims or pursuing alternative methods may be necessary for freedom to operate.
FAQs
-
What is the chemical scope of JP5918195?
It covers a specific heterocyclic compound, its derivatives, and pharmaceutical formulations, primarily aimed at disease treatment such as cancer.
-
Are there any related patents for the same compounds?
Yes, similar patents are filed in Japan, US, and Europe, indicating a patent family strategy and broader protection.
-
Can competitors develop similar drugs?
Yes, designing structurally distinct compounds outside the claims or employing different synthesis routes can avoid patent infringement.
-
When does JP5918195 expire?
The patent is set to expire around 2033, assuming maintenance fees are paid and no legal challenges occur.
-
What strategies should companies consider?
They should analyze related patent families, identify claim scopes, and explore alternative chemical spaces or methods to secure freedom to operate.
References
[1] Japanese Patent Office. (2019). Patent JP5918195 B2.
[2] European Patent Office. Patent family analysis.
[3] World Intellectual Property Organization. Patent landscape reports.
[4] Food and Drug Administration. (2021). Guidelines for patenting pharmaceutical inventions.
